[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.176.107. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Vignette
January 2006

Infliximab-Induced Lupus Erythematosus Tumidus in a Patient With Rheumatoid Arthritis

Arch Dermatol. 2006;142(1):109-116. doi:10.1001/archderm.142.1.115

Infliximab is a chimeric mouse-human monoclonal antibody targeting tumor necrosis factor α. It is approved for the treatment of refractory rheumatoid arthritis (RA), Crohn disease, ankylosing spondylitis, and psoriatic arthritis. Infliximab usually is well tolerated and has a good safety profile; only rare cases of severe adverse effects, including cardiac failure or mycobacterial infections, have been reported.1 A frequently observed and striking laboratory finding is the development of antinuclear antibodies, usually without clinical lupuslike symptoms.2

First Page Preview View Large
First page PDF preview
First page PDF preview
×